Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant.

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant.

Item

http://www.wikidata.org/entity/Q34753416

Q34753416

about

Lenalidomide treatment for multiple myeloma: systematic review and meta-analysis of randomized controlled trials First-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studies Appraisal of immunoglobulin free light chain as a marker of response Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis Carfilzomib/pomalidomide single-agent or in combination with other agents for the management of relapsed/refractory multiple myeloma : a meta-analysis of 37 trials Efficacy and Safety of Novel Agent-Based Therapies for Multiple Myeloma: A Meta-Analysis Deep Response in Multiple Myeloma: A Critical Review Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials New criteria for response assessment: role of minimal residual disease in multiple myeloma Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group Generation of a predictive melphalan resistance index by drug screen of B-cell cancer cell lines Proof of the concept to use a malignant B cell line drug screen strategy for identification and weight of melphalan resistance genes in multiple myeloma Outcome with lenalidomide plus dexamethasone followed by early autologous stem cell transplantation in patients with newly diagnosed multiple myeloma on the ECOG-ACRIN E4A03 randomized clinical trial: long-term follow-up.Response-adapted consolidation with bortezomib after ASCT improves progression-free survival in newly diagnosed multiple myeloma.Safety and tolerability of the antimicrobial peptide human lactoferrin 1-11 (hLF1-11)Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma.Impact of high-risk classification by FISH: an eastern cooperative oncology group (ECOG) study E4A03.Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial "Real-world" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group.Role of dynamic contrast-enhanced sonography for characterization and monitoring of extramedullary myeloma: comparison with serologic data.T cell progenitor therapy-facilitated thymopoiesis depends upon thymic input and continued thymic microenvironment interaction.Design and rationale of FOCUS (PX-171-011): a randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM)Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trials.Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics.Efficacy of single-agent bortezomib vs. single-agent thalidomide in patients with relapsed or refractory multiple myeloma: a systematic comparison.Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation.Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma.Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma.A pilot study of bortezomib in Korean patients with relapsed or refractory myeloma Liposomal daunorubicin and dexamethasone as a treatment for multiple myeloma--the DD Protocol.Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma.Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma.Bortezomib (Velcadetrade mark) in the Treatment of Multiple Myeloma Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma.Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells.

P2860

Q21133524-B0722B4B-F899-42DE-A542-4E14C8E7DE68 Q24197999-96FE8411-169C-464D-8BE8-E74A6537AEBF Q24624398-24876C64-DD91-45AD-BBFF-510823C7EDCD Q24647620-CDA4F57B-C472-4944-BAE1-AF3136D7BD65 Q24651269-E960135D-7557-49AB-8FCE-AC2C06569A30 Q24670135-0960254A-10BA-4EB1-B244-87C6BD3F8C5C Q26741620-5B6FF11F-5189-4112-8CE2-A3F0A15CCDA7 Q26767418-DBBFC30C-77A7-4B28-AD07-4ABD43F875B2 Q26771228-1C15C709-CF15-4ADB-A31D-87A4BC198287 Q26799104-3DF58414-30EC-4107-BD1E-50A9EAA29DA8 Q27002668-AC076F3B-AFAA-4022-B08E-0D54636AB5BC Q27024932-62AF62B3-2197-4214-BE7B-F300C69FA938 Q27027512-244B1E5D-4227-4D32-BF36-FF36DBEE9684 Q28194391-F93CD779-23C1-4088-90E2-F0C9B2102F4B Q28207984-682CE202-B8E4-4783-AEEE-119D8CE77AC4 Q28477988-79B1517C-A405-4E0D-8283-98B435853A1A Q28537857-68EFA9E8-0CD9-4530-BA11-E008D7827E64 Q30276010-54A974F1-BF14-4EB0-A2F1-538FF3D55821 Q30313340-8A667E8C-B0DE-4513-BD65-BCB2AEACE363 Q30397259-3034E2D1-960A-42BA-8C1E-6F6FAC296D4B Q30409713-246D6C2F-5A9E-4F38-903A-2204DE432074 Q30424188-106738B1-1D3F-4A51-B58D-E865512C0114 Q30433139-B83202E6-01D0-4B38-92FC-C8C2A7E9631F Q30657752-DD5019AC-AD27-454C-AB57-21270365870C Q30669943-74226A7D-D6C0-4B42-9DCB-909E9044EFFA Q30851570-C84322C4-85C3-436C-9880-7896D2770C0B Q31094748-7DA30B92-5297-48F9-A4DC-6BC6F0CE5606 Q31136560-614339A9-7155-46BC-A10E-9686988C1A2C Q33284138-253B53C6-4E0C-4F5C-8C8C-F1D62497677A Q33289791-8B13C3D7-9DBC-4E6C-8A69-F515B02D6E93 Q33322921-BCD041DB-6D59-405F-9249-E2D100689801 Q33364235-7491A786-93DF-44B8-B7DA-48B3FE02DE8B Q33367821-77448150-4916-4999-BFD6-E0BA357458DE Q33367833-F5330E27-22A6-4E6A-AD62-C40A9CA57D98 Q33370094-60FCBFBA-A0B5-4254-BA8F-893FE0E4F2C9 Q33374964-A33A1DFD-158C-4DA3-9E0B-C4C5CB9B9F36 Q33375805-008E0443-8170-4C58-8B0F-7602D62C33A5 Q33379044-03AC6324-D485-40A3-A46C-BC85B43CC5DA Q33383550-ECD8E6FA-DD64-45D5-9432-372E61E1E4AE Q33385308-EB7FC1F3-1AF6-40E5-819D-EBFC65D49C45

P2860

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant.

Item

http://www.wikidata.org/entity/Q34753416

description

1998 nî lūn-bûn

@nan

1998 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

1998 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

1998年の論文

@ja

1998年論文

@yue

1998年論文

@zh-hant

1998年論文

@zh-hk

1998年論文

@zh-mo

1998年論文

@zh-tw

1998年论文

@wuu